Skip to content

EBITDA margin at other companies

Johnson & Johnson logo
Johnson & JohnsonJNJ
34.4%+2.7pp
Glaukos logo
GlaukosGKOS
-28.5%+57.9pp
AbbVie logo
AbbVieABBV
37.3%
Bausch + Lomb logo
Bausch + LombBLCO
12.4%+1.9pp
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-9.2%-4.1pp
Boston Scientific logo
Boston ScientificBSX
25.2%+1.6pp

Other financials

Income statement

See full
Revenue$19.7M+12.5%
Gross profit$17.0M+12.5%
Operating income-$12.4M+10.4%
Net income-$13.0M+8.3%
EPS (diluted)-$0.24+14.3%

Balance sheet

See full
Cash & equivalents$85.0M-21.9%
Total debt$40.9M+1.1%
Total equity$53.9M-30.6%
Total assets$109.7M-15.4%

Cash flow

See full
Operating cash flow-$7.0M+39.4%
CapEx$60.0K
Free cash flow-$7.1M+38.9%

Valuation

See full
Market cap$294.9M+35.0%
Enterprise value$250.83M+59.0%
P/S3.7×+0.8×

Profitability

See full
Gross margin86.2%+0.5pp
Operating margin-44.8%-10.2pp
Net margin-46.8%-9.6pp
FCF margin-31.9%+0.2pp

Returns & leverage

See full
Return on equity-56.6%+4.3pp
Debt / equity0.8×+0.2×
Current ratio5.9×-4.6×

Where this comes from

Calculated from Sight Sciences, Inc.’s reported figures.

Based on trailing twelve months.

The official record: Sight Sciences, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Sight Sciences, Inc.'s ebitda margin.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Sight Sciences, Inc.'s EBITDA margin?
Sight Sciences, Inc. (SGHT) reported EBITDA margin of -44.3% in Q1 2026.
How has Sight Sciences, Inc.'s EBITDA margin changed year-over-year?
Sight Sciences, Inc.'s EBITDA margin increased by 29.4% year-over-year, from -62.7% to -44.3%.
What is the long-term trend for Sight Sciences, Inc.'s EBITDA margin?
Over 5 years (2020 to 2025), Sight Sciences, Inc.'s EBITDA margin has grown at a -16.2% compound annual growth rate (CAGR), from -114.5% to -47.3%.
What does EBITDA margin mean?
EBITDA (earnings before interest, taxes, depreciation, and amortization) as a percentage of revenue, trailing twelve months. A proxy for cash operating profitability that strips out capital-structure and non-cash charges.